Genedata partners with Life Technologies to expedite NGS data analysis and real-time PCR-based validation
(PRWEB) November 14, 2012
Basel, Switzerland: Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced a partnership with Life Technologies Corporation designed to create a streamlined ecosystem that empowers researchers in both academic and commercial settings to accelerate discovery and validation experiments. As part of the collaboration, Genedata will integrate Life Technologies’ online store with the Genedata biomarker discovery platforms Genedata Expressionist for Genomic Profiling and Genedata Analyst - enabling users to easily purchase TaqMan® real-time PCR assays specific to their next generation sequencing (NGS) data.
Within the Genedata/LifeTechnologies workflow, Genedata solutions process and analyze data and when marker candidates are identified, users seamlessly connect to the Life Technologies’ online store for TaqMan® Assay purchase. With a couple of clicks, PCR assays are selected and ordered for all marker candidates. Upon receipt of PCR assays, users can validate experiments in an integrative manner by loading the raw PCR data directly into the same session that was used for identifying marker candidates.
“Life Technologies and Genedata share a common goal of advancing research and facilitating scientific discovery,” said Chris Linthwaite, Head of Genetic Analysis at Life Technologies. “Integration of our complementary technologies serves that mission by providing researchers quick access to the most appropriate TaqMan assays to validate data from their NGS experiments.”
Thriving on large and complex experimental data sets, Genedata Expressionist for Genomic Profiling is easily integrated into existing research environments. The direct interface with TaqMan® real-time PCR assays is available for a variety of applications, including DNA-, RNA, Chip-, and Methyl-Seq, SNP genotyping, and copy number analysis.
“Our collaboration with Life Technologies reflects our vision to enrich the research experience for our customers with innovative solutions that also drive down costs with time-saving workflows,” noted Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Expressionist, researchers have the power of rich statistical and visualization tools to analyze NGS data, and these capabilities are now complemented with real-time PCR to quickly validate genomic experiments.”
TaqMan® real-time PCR assays are for Research Use Only. Not for use in diagnostic procedures.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10127741.htm